| Dr Rachael Dalya Hartman, MD | |
|
150 Park Ave, Florham Park, NJ 07932-1049 | |
| (973) 775-5156 | |
| Not Available |
| Full Name | Dr Rachael Dalya Hartman |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 17 Years |
| Location | 150 Park Ave, Florham Park, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568636314 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 25MA08898600 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Summit Medical Group Pa | 5395642276 | 1253 |
News Archive
Anaplastic thyroid carcinoma is an aggressive type of cancer with a poor prognosis for which there is currently no effective treatment. Researchers from the National University of Singapore have discovered for the first time that an epithelial basement membrane protein, called laminin-5 gamma-2 (LAMC2), has the potential to be an ideal target for the treatment of ATC.
Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has enrolled the first patient into its pivotal clinical trial with its new breakthrough compound of inhaled alpha-1 antitrypsin (AAT) delivered by an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in patients with alpha-1 antitrypsin deficiency.
Advances in diagnostic imaging technology have meant that more trauma patients are being diagnosed with blunt cerebrovascular injuries, and as a result, stroke and related death rates in these patients have declined significantly over the past 30 years.
Patients with high-risk chronic myeloid leukaemia who undergo allogeneic haematopoietic stem cell transplantation may benefit from continuing with tyrosine kinase inhibitor therapy, US clinicians believe.
A team of Yale Cancer Center researchers has confirmed that between 10-20% of breast cancers classified as Estrogen Receptor (ER) negative are really positive. Understanding when and why breast cancers may be misclassified has important implications for treatment and outcomes for women diagnosed with breast cancer. Its findings are published online in the June 28 Journal of Clinical Oncology.
› Verified 2 days ago
| Entity Name | Summit Medical Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942254347 PECOS PAC ID: 5395642276 Enrollment ID: O20031218000011 |
News Archive
Anaplastic thyroid carcinoma is an aggressive type of cancer with a poor prognosis for which there is currently no effective treatment. Researchers from the National University of Singapore have discovered for the first time that an epithelial basement membrane protein, called laminin-5 gamma-2 (LAMC2), has the potential to be an ideal target for the treatment of ATC.
Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has enrolled the first patient into its pivotal clinical trial with its new breakthrough compound of inhaled alpha-1 antitrypsin (AAT) delivered by an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in patients with alpha-1 antitrypsin deficiency.
Advances in diagnostic imaging technology have meant that more trauma patients are being diagnosed with blunt cerebrovascular injuries, and as a result, stroke and related death rates in these patients have declined significantly over the past 30 years.
Patients with high-risk chronic myeloid leukaemia who undergo allogeneic haematopoietic stem cell transplantation may benefit from continuing with tyrosine kinase inhibitor therapy, US clinicians believe.
A team of Yale Cancer Center researchers has confirmed that between 10-20% of breast cancers classified as Estrogen Receptor (ER) negative are really positive. Understanding when and why breast cancers may be misclassified has important implications for treatment and outcomes for women diagnosed with breast cancer. Its findings are published online in the June 28 Journal of Clinical Oncology.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rachael Dalya Hartman, MD 150 Park Ave, Florham Park, NJ 07932-1049 Ph: (973) 775-5156 | Dr Rachael Dalya Hartman, MD 150 Park Ave, Florham Park, NJ 07932-1049 Ph: (973) 775-5156 |
News Archive
Anaplastic thyroid carcinoma is an aggressive type of cancer with a poor prognosis for which there is currently no effective treatment. Researchers from the National University of Singapore have discovered for the first time that an epithelial basement membrane protein, called laminin-5 gamma-2 (LAMC2), has the potential to be an ideal target for the treatment of ATC.
Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has enrolled the first patient into its pivotal clinical trial with its new breakthrough compound of inhaled alpha-1 antitrypsin (AAT) delivered by an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in patients with alpha-1 antitrypsin deficiency.
Advances in diagnostic imaging technology have meant that more trauma patients are being diagnosed with blunt cerebrovascular injuries, and as a result, stroke and related death rates in these patients have declined significantly over the past 30 years.
Patients with high-risk chronic myeloid leukaemia who undergo allogeneic haematopoietic stem cell transplantation may benefit from continuing with tyrosine kinase inhibitor therapy, US clinicians believe.
A team of Yale Cancer Center researchers has confirmed that between 10-20% of breast cancers classified as Estrogen Receptor (ER) negative are really positive. Understanding when and why breast cancers may be misclassified has important implications for treatment and outcomes for women diagnosed with breast cancer. Its findings are published online in the June 28 Journal of Clinical Oncology.
› Verified 2 days ago
Dr. Brian Machler, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 128 Columbia Tpke, Suire 200, Florham Park, NJ 07932 Phone: 973-736-9535 Fax: 973-736-2607 | |
Dr. Shari Yaffa Sperling, D.O Dermatology Medicare: Accepting Medicare Assignments Practice Location: 222 Columbia Tpke, Florham Park, NJ 07932 Phone: 973-800-1948 Fax: 973-800-1949 | |
Dr. David Adam Kiken, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 205 Ridgedale Ave, Suite 4, Florham Park, NJ 07932 Phone: 973-301-9500 Fax: 973-301-0435 | |
Eric Y Huang, MD, PHD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 150 Park Ave, Florham Park, NJ 07932 Phone: 973-775-5156 |